

Guidance

Potassium Iodide as a Thyroid Blocking Agent in Radiation Emergencies

Additional copies are available from:

*Office of Training and Communications
Division of Communications Management
Drug Information Branch, HFD-210*

*5600 Fishers Lane
Rockville, MD 20857
(Tel) 301-827-4573*

(Internet) <http://www.fda.gov/cder/guidance/index.htm>

**U.S. Department of Health and Human Services
Food and Drug Administration
Center for Drug Evaluation and Research (CDER)**

**December 2000
Procedural**

TABLE OF CONTENTS

I. INTRODUCTION.....	1
II. BACKGROUND.....	1
III. DATA SOURCES	2
A. RELIANCE ON DATA FROM CHERNOBYL.....	2
B. THYROID CANCERS IN THE AFTERMATH OF CHERNOBYL.....	4
IV. CONCLUSIONS AND RECOMMENDATIONS	5
A. USE OF KI IN RADIATION EMERGENCIES: RATIONALE, EFFECTIVENESS, SAFETY.....	5
B. KI USE IN RADIATION EMERGENCIES: TREATMENT RECOMMENDATIONS.....	5
V. ADDITIONAL CONSIDERATIONS IN PROPHYLAXIS AGAINST THYROID RADIOIODINE EXPOSURE.....	7
VI. SUMMARY.....	8
BIBLIOGRAPHY.....	9

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42

Guidance¹

Iodide as a Thyroid Blocking Agent in Radiation Emergencies

This draft guidance, when finalized, will represent the Food and Drug Administration's current thinking on this topic. It does not create or confer any rights for or on any person and does not operate to bind FDA or the public. An alternative approach may be used if such approach satisfies the requirements of the applicable statutes and regulations.

I. INTRODUCTION

This guidance updates the Food and Drug Administration (FDA) recommendation on using potassium iodide (KI) to reduce the risk of thyroid cancer in radiation emergencies involving the release of radioactive iodine. The recommendations provide guidance to state and local governments and assist the Environmental Protection Agency in providing guidance to other federal agencies on the development of emergency-response plans for prevention of adverse effects to the thyroid from internal irradiation in the event that radioiodines are accidentally released into the environment. These recommendations address KI dosage and the projected radiation exposure at which the drug should be used.

The revised recommendations were prepared by the Potassium Iodide Working Group, comprising scientists from the FDA's Center for Drug Evaluation and Research (CDER) and Center for Devices and Radiological Health (CDRH) in collaboration with experts in the field from the National Institutes of Health (NIH). FDA's revised recommendations are in general accordance with those of the World Health Organization (WHO), as expressed in its *Guidelines for Iodine Prophylaxis Following Nuclear Accidents: Update 1999* (Baverstock 1999), although they differ in two respects (see section IV. B).

II. BACKGROUND

Under 44 CFR 351, the Federal Emergency Management Agency (FEMA) has established roles and responsibilities for Federal agencies in assisting State and local governments in their radiological emergency planning and preparedness activities. The Federal agencies, including the Department of Health and Human Services (HHS), are to carry out these roles and

¹ This guidance has been prepared by the Potassium Iodide Working Group in the Center for Drug Evaluation and Research (CDER) in cooperation with the Center for Devices and Radiological Health (CDRH) at the Food and Drug Administration.

43 responsibilities as members of the Federal Radiological Preparedness Coordinating Committee
44 (FRPCC). Under 44 CFR 351.23(f), HHS is directed to provide guidance to State and local
45 governments on the use of radioprotective substances and prophylactic use of drugs (e.g.,
46 potassium iodide (KI)) to reduce the radiation dose to specific organs. This guidance is to
47 include information about dosage and projected radiation exposures at which such drugs should
48 be used.

49
50 The FDA has provided guidance previously on the use of KI as a thyroid blocking agent. In the
51 *Federal Register* of December 15, 1978, FDA announced its conclusion that KI is a safe and
52 effective means by which to block uptake of radioiodines by the thyroid gland in a radiation
53 emergency under certain specified conditions of use. In the *Federal Register* of June 29, 1982,
54 FDA announced final recommendations on the administration of KI to the general public in a
55 radiation emergency. Those recommendations were formulated after reviewing studies relating
56 radiation dose to thyroid disease risk that rely on estimates of external thyroid irradiation after
57 the nuclear detonations at Hiroshima and Nagasaki and analogous studies among children who
58 had received therapeutic radiation to the head and neck. The final recommendations concluded
59 that at a projected dose to the thyroid gland of 25 cGy² or greater from ingested or inhaled
60 radioiodines, the risks of short-term use of small quantities of KI were outweighed by the
61 benefits of suppressing radioiodine-induced thyroid cancer. The amount of KI recommended at
62 that time was 130 mg per day for adults and children above 1 year of age and 65 mg per day for
63 children below 1 year of age. The guidance that follows revises our 1982 recommendations on
64 the use of KI for thyroid cancer prophylaxis based on comprehensive review of the data relating
65 radioiodine exposure to thyroid cancer risk accumulated in the aftermath of the 1986 Chernobyl
66 reactor accident.

67
68

69 III. DATA SOURCES

70
71

71 A. Reliance on Data from Chernobyl

72
73

73 The recommendations contained in this guidance are derived from our review of data that have
74 been reported in relation to the large number of thyroid cancers occurring as a result of the
75 Chernobyl reactor accident of April 1986. These are the most comprehensive and reliable data
76 available describing the relationship between thyroid radiation dose and risk for thyroid cancer.
77 We have included in this guidance an extensive bibliography of the sources used in developing
78 these revised recommendations.

79
80

80 In epidemiological studies investigating the relationship between thyroïdal radioiodine exposure
81 and risk of thyroid cancer, the estimation of thyroid radiation doses is a critical and complex
82 aspect of the analyses. Estimates of exposure, both for individuals and across populations, have
83 been reached in different studies by the variable combination of (1) direct thyroid measurements
84 in a segment of the exposed population; (2) measurements of I-131 concentrations in the milk
85 consumed by different groups (e.g., communities) and of the quantity of milk consumed; (3)
86 inference from ground deposition of long-lived radioisotopes released coincidentally and

² For the radiation produced by I-131, the radiation quality factor is approximately equal to 1, so that 1 cGy = 1 rem.

87 presumably in fixed ratios with radioiodines; and (4) reconstruction of the nature and extent of
88 the actual radiation release.

89

90 All estimates of individual and population exposure contain some degree of uncertainty. The
91 uncertainty is least for estimates of individual exposure based on direct thyroid measurements.
92 There is increasing uncertainty associated with estimates of community exposure that rely on
93 milk consumption estimates, and still greater uncertainty associated with community exposure
94 estimates derived by inference from ground deposition of long-lived radioisotopes. Exposure
95 estimates that rely heavily on release reconstructions are associated with the greatest uncertainty.
96 As explained below, the dosimetric data derived in the studies of individual and population
97 exposures following the Chernobyl accident, although not perfect, are unquestionably superior to
98 data from previous releases.

99

100 The Chernobyl reactor accident provides the best-documented example of a massive radiation
101 release in which large numbers of people across a broad geographical area were exposed acutely
102 to radioiodines released into the atmosphere. In contrast, the exposures resulting from radiation
103 releases from the Hanford Site in Washington State in the mid-1940s and in association with the
104 nuclear detonations at the Nevada Test Site in the 1950s were extended over years rather than
105 days to weeks, contributing to the difficulty in estimating radioactive dose in those potentially
106 exposed (Davis et al., 1999; Gilbert et al., 1998). The exposure of Marshall Islanders to fallout
107 from the nuclear detonation on Bikini in 1954 involved relatively few people, and although the
108 high rate of subsequent thyroid nodules and cancers in the exposed population was likely caused
109 in large part by radioiodines, the Marshall Islands data provide little insight into the dose-
110 response relationship between radioactive iodine exposure and thyroid cancer risk (Robbins and
111 Adams 1989).

112

113 Beginning within a week after the Chernobyl accident, direct measurements of thyroid exposure
114 were made in hundreds of thousands of individuals, across three republics of the former Soviet
115 Union (Robbins and Schneider 2000). Direct measurements of thyroid radioactivity are un-
116 available from the Hanford, Nevada Test Site, or Marshall Islands exposures. Indeed, the
117 estimates of thyroid radiation doses related to these releases rely heavily on release
118 reconstructions and, in the former two cases, on recall of the extent of milk consumption 40 to 50
119 years after the fact. In the Marshall Islands cohort, urinary radioiodine excretion data were
120 obtained and used in calculating exposure estimates. Milk consumption data were included as
121 components of some of the Chernobyl dosimetric analyses, but were complemented by critical
122 information from the direct thyroid measurements.

123

124 Because of the great uncertainty in the dose estimates from the Hanford and Nevada Test Site
125 exposures and due to the small numbers of thyroid cancers occurring in the populations
126 potentially exposed, the epidemiological studies of the excess thyroid cancer risk related to these
127 radioiodine releases are, at best, inconclusive. The results of these studies are inadequate to
128 refute overwhelming evidence from Chernobyl of a cause-effect relationship between thyroid
129 radioiodine deposition and thyroid cancer risk.

130

131 It is also notable that the thyroid radiation exposures after Chernobyl were virtually all internal,
132 from radioiodines. Despite some degree of uncertainty in the doses received, it is reasonable to

133 conclude that the contribution of external radiation was negligible for most individuals. This
134 distinguishes the Chernobyl exposures from those of the Marshall Islanders. Thus, the increase
135 in thyroid cancer seen after Chernobyl is directly attributable to ingested or inhaled radioiodines.
136 A comparable burden of excess thyroid cancers could conceivably accrue should U.S.
137 populations be similarly exposed in the event of a nuclear accident. This potential hazard
138 highlights the value of averting such risk by using KI as an adjunct to evacuation, sheltering, and
139 control of contaminated foodstuffs.

140

141 **B. Thyroid Cancers in the Aftermath of Chernobyl**

142

143 The Chernobyl reactor accident resulted in massive releases of I-131 and other radioiodines.
144 Beginning approximately 4 years after the accident, a sharp increase in the incidence of thyroid
145 cancer among children and adolescents in Belarus and Ukraine (areas covered by the radioactive
146 plume) was observed. In some regions, for the first 4 years of this striking increase, observed
147 cases of thyroid cancer among children aged 0-4 years at the time of the accident exceeded
148 expected cases by 30- to 60-fold. During the ensuing years, in the most heavily affected areas,
149 incidence is as much as 100-fold compared to pre-Chernobyl rates (Robbins and Schneider
150 2000). The majority of cases occurred in children who apparently received less than 30 cGy to
151 the thyroid (Astakhova et al., 1998). A few cases occurred in children exposed to estimated
152 doses of < 1 cGy; however, the uncertainty of these estimates and confounding by medical
153 radiation exposures leaves doubt as to the causal role of these doses of radioiodine (Souchkevitch
154 and Tsyb 1996).

155

156 We have concluded that the best dose-response information from Chernobyl shows a marked
157 increase in risk of thyroid cancer in children with exposures of 5 cGy or greater (Astakhova et
158 al., 1998; Ivanov et al., 1999; Kazakov et al., 1992). Among children born more than 6 months
159 after the accident in areas traversed by the radioactive plume, the incidence of thyroid cancer has
160 not exceeded preaccident rates, consistent with the short half-life of I-131.

161

162 The use of KI in Poland after the Chernobyl accident provides us with useful information
163 regarding its safety and tolerability in the general population. Approximately 10.5 million
164 children under age 16 and 7 million adults received at least one dose of KI. Of note, among
165 newborns receiving single doses of 15 mg KI, 0.37% (12/3214) showed transient increases in
166 TSH (thyroid stimulating hormone) and decreases in FT4 (free thyroxine). The side effects
167 among adults and children were generally mild and not clinically significant. Side effects
168 included gastrointestinal distress, which was reported more frequently in children (up to 2
169 percent) and rash (~1 percent in children and adults). Two allergic reactions were observed in
170 adults with known iodine sensitivity (Nauman and Wolff 1993).

171

172 Thus, the studies following the Chernobyl accident support the etiologic role of relatively small
173 doses of radioiodine in the dramatic increase in thyroid cancer among exposed children.
174 Furthermore, it appears that the increased risk occurs with a relatively short latency. Finally, the
175 Polish experience supports the use of KI as a safe and effective means by which to protect
176 against thyroid cancer caused by internal thyroid irradiation from inhalation of contaminated air
177 or ingestion of contaminated food and drink when exposure cannot be prevented by evacuation,
178 sheltering, or food and milk control.

179
180
181
182
183
184
185
186
187
188
189
190
191
192
193
194
195
196
197
198
199
200
201
202
203
204
205
206
207
208
209
210
211
212
213
214
215
216
217
218
219
220
221
222
223

IV. CONCLUSIONS AND RECOMMENDATIONS

A. Use of KI in radiation emergencies: rationale, effectiveness, safety

The direct relationship between exposure to inhaled or ingested radioiodines and thyroid cancer risk, if ever in doubt, is firmly established in the aftermath of the 1986 Chernobyl accident. For the reasons discussed above, the Chernobyl data provide the most reliable information available to date on the relationship between internal thyroid radioactive dose and cancer risk. They suggest that the risk of thyroid cancer is inversely related to age, and that, especially in young children, it may accrue at very low levels of radioiodine exposure. We have relied on the Chernobyl data to formulate our specific recommendations below.

The effectiveness of KI as a specific blocker of thyroid radioiodine uptake is well-established (Sternthal et al., 1980) as are the doses necessary for blockade. As such, it is reasonable to conclude that KI will likewise be effective in reducing the risk of thyroid cancer in individuals or populations at risk for inhalation or ingestion of radioiodines.

Short-term administration of KI at thyroid-blocking doses is safe and, in general, more so in children than adults. The risks of stable iodine administration include sialadenitis (of which no cases were reported in Poland among users after the Chernobyl accident), GI disturbances, and minor rashes. In addition, persons with known iodide sensitivity should avoid KI, as should individuals with dermatitis herpetiformis and hypocomplementemic vasculitis, extremely rare conditions associated with an increased risk of iodine hypersensitivity.

Thyroidal side effects of stable iodine include iodide-induced thyrotoxicosis, which is more common in older people and in iodide-deficient areas and usually requires repeated doses of stable iodine. In addition, iodide goiter and hypothyroidism, potential side effects more common in iodine-sufficient areas, require chronic high doses of stable iodine (Rubery 1990). In light of the preceding, individuals with multinodular goiter, Graves' disease, and autoimmune thyroiditis should be treated with caution, especially if dosing extends beyond a few days. The vast majority of such individuals will be adults.

The transient hypothyroidism observed in 0.37 percent (12/3214) of neonates treated with KI in Poland after Chernobyl has been without sequelae to date. There is no question that the benefits of KI treatment to reduce the risk of thyroid cancer outweigh the risks of such treatment in neonates. Nevertheless, in light of the potential consequences of even transient hypothyroidism for intellectual development, we recommend that neonates (within the first month of life) treated with KI be monitored for this effect by measurement of TSH (and FT4, if indicated) and that thyroid hormone therapy be instituted in cases in which hypothyroidism develops (Fisher, Calaciura).

B. KI use in radiation emergencies: treatment recommendations

224 After careful review of the data from Chernobyl relating estimated thyroid radiation dose and
 225 cancer risk in exposed children, FDA recommends administration of KI to children aged 0-18
 226 years and pregnant or lactating women in the event of a projected radiation dose to the thyroid of
 227 5 cGy or greater. For adults up to 40 years of age, KI should be administered at a projected
 228 radiation dose of 10 cGy or greater. Adults over 40 need only take KI in the case of a projected
 229 large internal radiation dose to the thyroid (≥ 500 cGy) to prevent hypothyroidism (see table).
 230
 231

Threshold Thyroid Radioactive Exposures and Recommended Doses of KI for Different Risk Groups				
	Predicted Thyroid exposure(cGy)	KI dose (mg)	# of 130 mg tablets	# of 65 mg tablets
Adults over 40 yrs	≥ 500	130	1	2
Adults over 18-40 yrs	≥ 10			
Pregnant or lactating women	≥ 5			
Adolesc. over 12-18 yrs*	≥ 5	65	1/2	1
Children over 3-12 yrs		32	1/4	1/2
over 1 month-3 years		16	1/8	1/4
birth-1 month				

232 * adolescents approaching adult size (≥ 70 kg) should receive the full adult dose (130 mg)
 233
 234

235 These FDA recommendations differ from those put forward in the World Health Organization
 236 (WHO) 1999 guidelines for iodine prophylaxis in two areas. WHO recommends the 130 mg
 237 dose of KI for adults and adolescents (over 12 years). For the sake of logistical simplicity in the
 238 dispensing and administration of KI to children, FDA recommends the 65 mg dose as standard
 239 for all school-age children while allowing for the adult dose (130 mg, 2 X 65 mg tablets) in
 240 adolescents approaching adult size. The other difference lies in the threshold for predicted
 241 exposure to those up to 18 years of age and to pregnant or lactating women that will trigger KI
 242 prophylaxis. WHO recommends a 1 cGy threshold for this group. As stated earlier, FDA has
 243 concluded from the Chernobyl data that the most reliable evidence supports a significant increase
 244 in the risk of childhood thyroid cancer at exposures of 5 cGy or greater.
 245

246 The downward KI dose adjustment by age group, based on body size considerations, adheres to
 247 the principle of minimum effective dose. The recommended standard dose of KI for all school-
 248 age children is the same (65 mg). However, adolescents approaching adult size (i.e., ≥ 70 kg)
 249 should receive the full adult dose (130 mg) for maximal blockade of thyroid radioiodine uptake.
 250 Neonates ideally should receive the lowest dose (16 mg) of KI to minimize the risk of
 251 hypothyroidism during that critical phase of brain development (Calaciura et al., 1995). KI from
 252 tablets (either whole or fractions) or as fresh saturated KI solution may be diluted in milk or
 253 water and the appropriate volume administered to babies. As stated above, we recommend that
 254 neonates (within the first month of life) treated with KI be monitored for the potential

255 development of hypothyroidism by measurement of TSH (and FT4, if indicated) and that thyroid
256 hormone therapy be instituted in cases in which hypothyroidism develops (Fisher 2000;
257 Calaciura et al., 1995).

258

259 Pregnant women should be given KI for their own protection and for that of the fetus, as iodine
260 (whether stable or radioactive) readily crosses the placenta. However, because of the risk of
261 blocking fetal thyroid function with excess stable iodine, repeat dosing with KI of pregnant
262 women should be avoided. Lactating females should be administered KI for their own
263 protection, as for other young adults, potentially to reduce the radioiodine content of the breast
264 milk, but not as a means to deliver KI to infants, who should get their KI directly. As for direct
265 administration of KI, stable iodine as a component of breast milk may also pose a risk of
266 hypothyroidism in nursing neonates. Therefore, if repeat dosing of the mother is necessary, the
267 nursing neonate should be monitored as recommended above.

268

269 The protective effect of KI lasts approximately 24 hours. For optimal prophylaxis, KI should
270 therefore be dosed daily, until a risk of significant exposure to radioiodines by either inhalation
271 or ingestion no longer exists. Individuals intolerant of KI at protective doses and pregnant and
272 lactating women (in whom repeat administration of KI raises particular safety issues, see above)
273 should be given priority with regard to other protective measures (i.e., sheltering, evacuation, and
274 control of the food supply).

275

276

277 **V. ADDITIONAL CONSIDERATIONS IN PROPHYLAXIS AGAINST THYROID** 278 **RADIOIODINE EXPOSURE**

279

280 Certain principles should guide emergency planning and implementation of KI prophylaxis in the
281 event of a radiation emergency. After the Chernobyl accident, across the affected populations,
282 thyroid radiation exposures occurred largely due to consumption of contaminated fresh cow's
283 milk (this contamination was the result of grazing on fields affected by radioactive fallout) and to
284 a much lesser extent by consumption of contaminated vegetables. In this or similar accidents,
285 for those residing in the immediate area of the accident or otherwise directly exposed to the
286 radioactive plume, inhalation of radioiodines may be a significant contributor to individual and
287 population exposures. As a practical matter, however, the risk of thyroid exposure from inhaled
288 radioiodines can only be assessed in retrospect, as it depends upon factors such as the magnitude
289 and rate of the radioiodine release, wind direction and other atmospheric conditions, and thus
290 may affect people both near to and far from the accident site.

291

292 For optimal protection against inhaled radioiodines, KI should be administered before or
293 immediately coincident with passage of the radioactive cloud, though KI may still have a
294 substantial protective effect even if taken 3 or 4 hours after exposure. Furthermore, if the release
295 of radioiodines into the atmosphere is protracted, then, of course, even delayed administration
296 may reap benefits by reducing, if incompletely, the total radiation dose to the thyroid.

297

298 Prevention of thyroid uptake of ingested radioiodines, once the plume has passed and radiation
299 protection measures (including KI) are in place, is best accomplished by food control measures
300 and not by repeated administration of KI. Because of radioactive decay, grain products and

301 canned milk or vegetables from sources affected by radioactive fallout, if stored for weeks to
302 months after production, pose no radiation risk. Thus, late KI prophylaxis at the time of
303 consumption is not required.

304

305 As time is of the essence in optimal prophylaxis with KI, timely administration to the public is a
306 critical consideration in planning the emergency response to a radiation accident.

307

308

309 **VI. SUMMARY**

310

311 FDA maintains that KI is a safe and effective means by which to prevent radioiodine uptake by
312 the thyroid gland, under certain specified conditions of use, and thereby obviate the risk of
313 thyroid cancer in the event of a radiation emergency. Based upon review of the literature, we
314 have proposed lower radioactive exposure thresholds for KI prophylaxis as well as lower doses
315 of KI for neonates, infants, and children than we recommended in 1982. As in our 1982 notice
316 in the *Federal Register*, FDA continues to recommend that radiation emergency response plans
317 include provisions, in the event of a radiation emergency, for informing the public about the
318 magnitude of the radiation hazard, about the manner of use of KI and its potential benefits and
319 risks, and for medical contact, reporting, and assistance systems. FDA also emphasizes that
320 emergency response plans and any systems for ensuring availability of KI to the public should
321 recognize the critical importance of KI administration in advance of exposure to radioiodine. As
322 in the past, FDA continues to work in an ongoing fashion with manufacturers of KI to ensure that
323 high-quality, safe, and effective KI products are available for purchase by consumers as well as
324 by state and local governments wishing to establish stores for emergency distribution.

325

326 KI provides protection only for the thyroid from radioiodines. It has no impact on the uptake by
327 the body of other radioactive materials and provides no protection against external irradiation of
328 any kind. FDA emphasizes that the use of KI should be as an adjunct to evacuation (itself not
329 always feasible), sheltering, and control of foodstuffs.

330

331 **ACKNOWLEDGEMENTS**

332

333 The KI Taskforce would like to extend special thanks to our members from the NIH: Drs. Jacob
334 Robbins and Jan Wolff of the National Institute of Diabetes, Digestive, and Kidney Diseases and
335 Dr. Andre Bouville of the National Cancer Institute. In addition, we would like to thank Dr.
336 David Becker of the New York Hospital, Cornell Medical Center for his valuable comments on
337 the draft.

BIBLIOGRAPHY

338
339
340
341
342
343
344
345
346
347
348
349
350
351
352
353
354
355
356
357
358
359
360
361
362
363
364
365
366
367
368
369
370
371
372
373
374
375
376
377
378
379
380
381
382

Astakhova LN, Anspaugh LR, Beebe GW, Bouville A, Drozdovitch VV, Garber V, Gavrilin YI, Khrouch VT, Kuvshinnikov AV, Kuzmenkov YN, Minenko VP, Moschik KV, Nalivko AS, Robbins J, Shemiakina EV, Shinkarev S, Tochitskaya VI, Waclawiw MA. "Chernobyl-Related Thyroid Cancer in Children in Belarus: A Case-Control Study." *Radiat Res* 1998; 150:349-356.

Baverstock K. *Guidelines for Iodine Prophylaxis following Nuclear Accidents: Update 1999*. World Health Organization, Geneva, 1999.

Baverstock K, Egloff B, Pinchera A, Ruchti C, Dillwyn W. "Thyroid Cancer After Chernobyl" (letter to the editor). *Nature* 1992; 359:21-22.

Becker DV, Robbins J, Beebe GW, Bouville AC, Wachholz BW. "Childhood Thyroid Cancer Following the Chernobyl Accident: A Status Report." *Endocrinol Metab Clin North Am* 1996; 25(1): 197-211.

Bongers-Schokking JJ, Koot HM, Wiersma D, Verkerk PH, de Muinck Keizer-Schrama SMPF. "Influence of timing and dose of thyroid hormone replacement on development in infants with congenital hypothyroidism." *J Pediatrics* 2000; 136(3): 292-297.

Calaciura F, Mendoria G, Distefano M, Castorina S, Fazio T, Motta RM, Sava L, Delange F, Vigneri R. "Childhood IQ Measurements in Infants With Transient Congenital Hypothyroidism." *Clin Endocrinol* 1995;43:473-477.

Davis S, Kopecky KJ, Hamilton T, Amundson B, Myers PA. *Summary Final Report of the Hanford Thyroid Disease Study*. Seattle: Fred Hutchinson Cancer Research Center, 1999.

Fisher DA. "The importance of early management in optimizing IQ in infants with congenital hypothyroidism." *J Pediatrics* 2000; 136(3): 273-274.

Gavrilin YI, Khrouch VT, Shinkarev SM, Krysenko NA, Skryabin AM, Bouville A, Anspaugh LR. "Chernobyl Accident: Reconstruction of Thyroid Dose for Inhabitants of the Republic of Belarus." *Health Phys* 1999; 76(2):105-119.

Gilbert ES, Tarone R, Bouville A, Ron E. "Thyroid Cancer Rates and 131-I Doses From Nevada Atmospheric Nuclear Bomb Tests." *J Natl Cancer Inst* 1998; 90(21): 1654-60.

Harrison JR, Paile W, Baverstock K. Public Health Implications of Iodine Prophylaxis in Radiological Emergencies. In: "Thomas G, Karaoglou A, Williams ED.", eds. *Radiation and Thyroid Cancer*. Singapore: World Scientific, 1999; 455-463.

- 383 Il'in LA, Arkhangel'skaya GV, Konstantinov YO, Likhtarev IA. *Radioactive Iodine in the*
384 *Problem of Radiation Safety*. Moscow, Atomizdat 1972; 208-229.
385
- 386 Ivanov VK, Gorski AI, Pitkevitch VA, Tsyb AF, Cardis E, Storm H. "Risk of Radiogenic
387 Thyroid Cancer in Russia Following the Chernobyl Accident." In: Thomas G, Karaoglou
388 A, Williams ED., eds. *Radiation and Thyroid Cancer*. Singapore: World Scientific,
389 1999; 89-96.
390
- 391 Jacob P, Goulko G, Heidenreich WF, Likhtarev I, Kairo I, Tronko ND, Bogdanova TI,
392 Kenigsberg J, Buglova E, Drozdovitch V, Goloneva A, Demidchik EP, Balonov M,
393 Zvonova I, Beral V., "Thyroid Cancer Risk to Children Calculated." *Nature* 1998;
394 392:31-32.
395
- 396 Kazakov VS, Demidchik EP, Astakhova LN. "Thyroid Cancer After Chernobyl" (letter to the
397 editor). *Nature* 1992; 359:21.
398
- 399 Likhtarev IA, Sobolev BG, Kairo IA, Tronko ND, Bogdanova TI, Olelnic VA, Epshtein EV,
400 Beral V. "Thyroid Cancer in the Ukraine." *Nature* 1995; 375:365.
401
- 402 Mettler FH, Becker DV, Walchholz BW, Bouville AC., "Chernobyl: 10 Years Later." *J Nucl*
403 *Med* 1996; 37:24N-27N.
404
- 405 Nauman J, Wolff J. "Iodide Prophylaxis in Poland After the Chernobyl Reactor Accident:
406 Benefits and Risks." *Am J Med* 1993; 94: 524-532.
407
- 408 Robbins J, Adams WH. "Radiation Effects in the Marshall Islands." In: Nagataki S, ed.
409 *Radiation and the Thyroid. Proceedings of the 27th Annual Meeting of the Japanese*
410 *Nuclear Medicine Society*. Amsterdam, Excerpta Medica, 1989; 11-24.
411
- 412 Robbins J, Schneider AB. "Thyroid Cancer following Exposure to Radioactive Iodine."
413 *Reviews in Endocrine and Metabolic Disorders* 2000; 1:197-203.
414
- 415 Rubery ED. "Practical Aspects of Prophylactic Stable Iodine Usage." In: Rubery E, Smales E.,
416 eds. *Iodine Prophylaxis Following Nuclear Accidents: Proceedings of a Joint WHO/CEC*
417 *Workshop*. Oxford, Pergamon Press, 1990; 141-150.
418
- 419 Souchkevitch GN, Tsyb AI., eds. *Health Consequences of the Chernobyl Accident: Scientific*
420 *Report*. World Health Organization, Geneva, 1996; 248-250.
421
- 422 Stepanenko V, Tsyb A, Skvortsov V, Kondrashov A, Shakhtarin V, Hoshi M, Ohtaki M,
423 Matsuura M, Takada J, Endo S. "New Results of Thyroid Retrospective Dosimetry in
424 Russia Following the Chernobyl Accident." In: Thomas G, Karaoglou A, Williams ED.,
425 eds. *Radiation and Thyroid Cancer*. Singapore: World Scientific, 1999; 333-339.
426

- 427 Sternthal E, Lipworth L, Stanley B, Abreau C, Fang S-L, Braverman LE. "Suppression of
428 Thyroid Radioiodine Uptake by Various Doses of Stable Iodine." *N Engl J Med* 1980;
429 303:1083-8.
430
- 431 Stsjazhko VA, Tsyb AF, Tronko ND, Souchkevitch G, Baverstock K. "Childhood Thyroid
432 Cancer Since Accident at Chernobyl." *BMJ* 1995; 310:801.
433
- 434 Williams ED, Becker D, Dimidchik EP, Nagataki S, Pinchera A, Tronko ND. "Effects on the
435 Thyroid in Populations Exposed to Radiation as a Result of the Chernobyl Accident." In:
436 *One Decade After Chernobyl: Summing up the Consequence of the Accident*. Vienna,
437 International Atomic Energy Agency, 1996; 207-230.
438
- 439 "Report on the Joint WHO/CEC Workshop on Iodine Prophylaxis following Nuclear Accidents:
440 Rationale for Stable Iodine Prophylaxis." In: Rubery E, Smales E., eds. *Iodine*
441 *Prophylaxis following Nuclear Accidents: Proceedings of a joint WHO/CEC Workshop*.